NKTX logo

NKTX Nkarta, Inc.

NASDAQ · Biotechnology · Healthcare

$1.14
+0.01 (+1.34%)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myop…

Market Cap: $81.29Mwww.nkartatx.com

Price

No data yet.

Social Signal Score

44
5d
—
30d
43
3 mentions
—
60d
45
4 mentions
—
90d
42
5 mentions
—
news: 5

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 1Buy 9Hold 2Sell 0Strong Sell 0
Avg price target$9+693.0%
Low $9Median $9High $9
Current Consensus

Revenue

$0.00-100.00%
$-385.00$37.4K$75.3K$113.1K
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.31
$-1.39–$-1.16
4 analysts
FY2026
$-1.76
$-1.95–$-1.32
4 analysts
FY2027
$-1.41
$-1.75–$-0.72
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Paul J. Hastings
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
0.97
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-3.76
www.nkartatx.com